Potential diagnostic pitfalls of bone scintigraphy in transthyretin-related amyloidosis

CC BY-NC-ND 4.0 · World J Nucl Med 2020; 19(03): 313-314
DOI: 10.4103/wjnm.WJNM_25_20

Letter to Editor

Georgios Meristoudis

Department of Nuclear Medicine, Hippokration General Hospital, Thessaloniki

,

Ioannis Ilias

¹Department of Endocrinology, Elena Venizelou General Hospital, Athens, Greece

,

Georgia Keramida

²Department of Nuclear Medicine, Royal Brompton and Harefield Hospital, London, United Kingdom

References
1 Kuria IM, Gitau SN, Makhdomi KB. Bone scintigraphy imaging of cardiac amyloidosis. World J Nucl Med 2019;18:314-6.
2 Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation 2016;133:2404-12.
3 Gnanasegaran G, Cook G, Adamson K, Fogelman I. Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT/CT. Semin Nucl Med 2009;39:380-95.
4 Vallabhajosula S, Killeen RP, Osborne JR. Altered biodistribution of radiopharmaceuticals: Role of radiochemical/pharmaceutical purity, physiological, and pharmacologic factors. Semin Nucl Med 2010;40:220-41.
5 Qutbi M, Shafiei B, Khoshbakht S, Asadi A, Neshandar Asli I. An unexpected and less recognized altered distribution on bone scintigraphy; possibility of ^99mTc dextrose complex as a cause. Clin Nucl Med 2017;42:952-7.